Oncolytics Biotech Inc. Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Aug 11, 2025 · CIK: 1129928
Sentiment: neutral
Topics: corporate-filing, foreign-private-issuer, sec-filing
Related Tickers: ONCY
TL;DR
Oncolytics Biotech Inc. (ONCY) filed a 6-K, confirming its Canadian base and SEC reporting requirements.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on August 11, 2025, reporting its status as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and its principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, T2R 0C5. Oncolytics Biotech Inc. is required to file annual reports under Form 20-F.
Why It Matters
This filing provides routine corporate information for Oncolytics Biotech Inc., confirming its status and location as a foreign private issuer for SEC reporting purposes.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate information and does not contain new financial or operational data that would typically impact risk.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- August 2025 (date) — Reporting period
- Calgary, Alberta, Canada (location) — Company headquarters
- Form 6-K (document) — Filing type
- Form 20-F (document) — Required annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer, including its status and location, for the month of August 2025.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What type of annual report does Oncolytics Biotech Inc. file?
Oncolytics Biotech Inc. files its annual reports under cover of Form 20-F.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Is Oncolytics Biotech Inc. submitting this Form 6-K in paper format?
The filing does not indicate that the Form 6-K is being submitted in paper format under Regulation S-T Rule 101(b)(1).
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-08-11 17:14:15
Filing Documents
- form6kagm2025agmresults.htm (6-K) — 17KB
- agm2025resultspr.htm (EX-99.1) — 24KB
- 0001129928-25-000068.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date August 11, 2025 Kirk Look Chief Financial Officer